MedTrace Logo

Efficacy and Safety of First-line ART With BIC/FTC/TAF Introduced at the First Clinical Visit

NCT06518213 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 112

Last updated 2024-07-24

No results posted yet for this study

Summary

Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a recommended first-line antiretroviral regimen. Croatia has a centralized care for people living with HIV (PLWH) and all persons are seen and treated in a single center, preferably in a same-day initiation model whenever suitable. This retrospective cohort study evaluated antiretroviral therapy (ART) naïve PLWH who initiated BIC/FTC/TAF, in a same-day model. The goal of the study is to assess safety and efficacy of this model by collecting information from the electronic database of the Croatian HIV Reference Centre.

Conditions

  • HIV Infections

Sponsors & Collaborators

  • University Hospital for Infectious Diseases, Croatia

    lead OTHER

Principal Investigators

  • Josip Begovac, Prof. · University Hospital for Infectious Diseases ''Dr. Fran Mihaljevic''

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2022-12-31
Completion
2024-03-31

Countries

  • Croatia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06518213 on ClinicalTrials.gov